Can lumateperone (Caplyta®) cause metabolic side effects?

Lumateperone (US brand name Caplyta®) is a second-generation (“atypical”) antipsychotic that was approved by the FDA in 2019. For basic information about it, please see the following article on this website: Lumateperone (Caplyta®): Basic information When a new antipsychotic is introduced, the obvious question is whether it is either more effective than previously available ones…